skip to main content
Idioma:
Refinado por: Base de dados/Biblioteca: Wiley Online Library All Journals remover tipo de recurso: Anais de Congresso remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Staphylococcal Enterotoxins sensitization and response of Omalizumab in severe atopic and non atopic asthma
Staphylococcal Enterotoxins sensitization and response of Omalizumab in severe atopic and non atopic asthma
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Staphylococcal Enterotoxins sensitization and response of Omalizumab in severe atopic and non atopic asthma

Migueres, N ; Poirot, A ; Zhang, N ; Bachert, C ; De Blay, F

EUROPEAN RESPIRATORY JOURNAL, 2021, Vol.58 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
2
ARTEMIS: A European, Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial of AR101 in Peanut-Allergic Children and Adolescents Aged 4-17
ARTEMIS: A European, Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial of AR101 in Peanut-Allergic Children and Adolescents Aged 4-17
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

ARTEMIS: A European, Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial of AR101 in Peanut-Allergic Children and Adolescents Aged 4-17

Vereda, A ; Fernandez-Rivas, M ; Hourihane, JO ; Turner, P ; Blumchen, K ; Nilsson, C ; Ibanez, MD ; Deschildre, A ; Muraro, A ; Sharma, V ; Erlewyn-Lajeunesse, M ; Zubeldia, JM ; De Blay, F ; Sauvage, CD ; Byrne, A ; Chapman, J ; Boralevi, F ; Abbas, A ; Norval, D ; Hylands, K ; du Toit, G ; Beyer, K

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, Vol.18, p.8 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
3
Treatment satisfaction with AR101 oral immunotherapy for peanut allergy in a European paediatric population
Treatment satisfaction with AR101 oral immunotherapy for peanut allergy in a European paediatric population
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Treatment satisfaction with AR101 oral immunotherapy for peanut allergy in a European paediatric population

Sharma, V ; Du Toit, G ; Fernandez-Rivas, M ; Beyer, K ; Turner, PJ ; Blumchen, K ; Nilsson, C ; Ibanez, MD ; Deschildre, A ; Muraro, A ; Erlewyn-Lajeunesse, M ; Zubeldia, JM ; De Blay, F ; Sauvage, CD ; Byrne, A ; Chapman, J ; Boralevi, F ; Norval, D ; Adelman, DC ; Hourihane, JO

ALLERGY, 2020, Vol.75, p.37 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
4
ARTEMIS: A European, phase 3, randomised, double-blind, placebo-controlled trial of AR101 in peanut-allergic children and adolescents aged 4-17
ARTEMIS: A European, phase 3, randomised, double-blind, placebo-controlled trial of AR101 in peanut-allergic children and adolescents aged 4-17
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

ARTEMIS: A European, phase 3, randomised, double-blind, placebo-controlled trial of AR101 in peanut-allergic children and adolescents aged 4-17

Fernandez-Rivas, MM ; Hourihane, JO ; Beyer, K ; Turner, P ; Blumchen, K ; Nilsson, C ; Ibanez, MD ; Deschildre, A ; Muraro, A ; Sharma, V ; Erlewyn-Lajeunesse, M ; Zubeldia, JM ; De Blay, F ; Delebarre, CS ; Byrne, A ; Chapman, J ; Boralevi, F ; Abbas, A ; Norval, D ; Vereda, A ; Mcintosh, S ; Du Toit, G

ALLERGY, 2019, Vol.74, p.16 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
5
ARTEMIS: a European, Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial of AR101 in peanut-allergic children and adolescents aged 4-17 years
ARTEMIS: a European, Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial of AR101 in peanut-allergic children and adolescents aged 4-17 years
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

ARTEMIS: a European, Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial of AR101 in peanut-allergic children and adolescents aged 4-17 years

du Toit, G ; Hourihane, JOB ; Beyer, K ; Turner, P ; Blumchen, K ; Nilsson, C ; Ibanez, MD ; Deschildre, A ; Muraro, A ; Sharma, V ; Erlewyn-Lajeunesse, M ; Zubeldia, JM ; De Blay, F ; Sauvage, CD ; Byrne, A ; Chapman, J ; Boralevi, F ; Abbas, A ; Norval, D ; Fernandez-Rivas, M

CLINICAL AND EXPERIMENTAL ALLERGY, 2019, Vol.49 (12), p.1676 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
6
Cluster analysis and principal component analysis to access the variability of data in cost evaluations: methods and applications in oncology
Cluster analysis and principal component analysis to access the variability of data in cost evaluations: methods and applications in oncology
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Cluster analysis and principal component analysis to access the variability of data in cost evaluations: methods and applications in oncology

Perrier, Lionel ; Buja, Alessandra ; Mastrangelo, Giuseppe ; Sylvestre-Baron, Patrick ; Pauwels, Petrus ; Rossi, Carlo ; Gilly, François ; Ducimetière, Françoise ; Favier, Bertrand ; Farsi, Fadila ; Laramas, Mathieu ; de Marliave, Hugues ; Collard, Olivier ; Cellier, Dominic ; Blay, Jean-Yves ; Ray-Coquard, Isabelle

Value in Health, 2012, Vol.15 (7) [Periódico revisado por pares]

Elsevier

Texto completo disponível

Citações Citado por
7
Efficacy against asthma demonstrated for a house dust mite allergen immunotherapy tablet
Efficacy against asthma demonstrated for a house dust mite allergen immunotherapy tablet
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

Efficacy against asthma demonstrated for a house dust mite allergen immunotherapy tablet

Mosbech, H. ; de Blay, F. ; Deckelmann, R. ; Korsgaard, J. ; Malcus, Inga ; Pastorello, E. ; Andres, L. ; Trebas-Pietras, E. ; Andersen, B. ; Canonica, G.

28th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology,2009-06-06 - 2009-06-10, 2009, Vol.64, p.434 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.